padsevonil

{{cs1 config|name-list-style=vanc|display-authors=6}}

{{Infobox drug

| drug_name =

| image = Padsevonil v2.svg

| width =

| caption =

| pronounce =

| tradename =

| Drugs.com =

| MedlinePlus =

| licence_CA =

| licence_EU =

| DailyMedID =

| licence_US =

| pregnancy_AU =

| pregnancy_category =

| dependency_liability =

| addiction_liability =

| routes_of_administration = Oral

| class = Synaptic vesicle glycoprotein 2A (SV2A) ligand

| ATC_prefix =

| ATC_suffix =

| legal_status =

| bioavailability =

| protein_bound =

| metabolism =

| metabolites =

| onset =

| elimination_half-life =

| duration_of_action =

| excretion =

| CAS_number = 1294000-61-5

| CAS_supplemental =

| PubChem = 52911611

| PubChemSubstance =

| IUPHAR_ligand =

| DrugBank = DB14977

| ChemSpiderID = 58828036

| UNII = 0R1HN52K0N

| KEGG = D11842

| ChEBI =

| ChEMBL = 4297521

| NIAID_ChemDB =

| PDB_ligand =

| synonyms = UCB-0942; UCB0942; UCB1415943-000

| IUPAC_name = (4R)-4-(2-chloro-2,2-difluoroethyl)-1-[[2-(methoxymethyl)-6-(trifluoromethyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]methyl]pyrrolidin-2-one

| C=14 | H=14 | Cl=1 | F=5 | N=4 | O=2 | S=1

| SMILES = COCC1=NN2C(=C(N=C2S1)C(F)(F)F)CN3C[C@H](CC3=O)CC(F)(F)Cl

| StdInChI = 1S/C14H14ClF5N4O2S/c1-26-6-9-22-24-8(11(14(18,19)20)21-12(24)27-9)5-23-4-7(2-10(23)25)3-13(15,16)17/h7H,2-6H2,1H3/t7-/m1/s1

| StdInChIKey = DCXFIOLWWRXEQH-SSDOTTSWSA-N

}}

Padsevonil ({{Abbrlink|INN|International Nonproprietary Name}}, {{Abbrlink|USAN|United States Adopted Name}}, {{Abbrlink|JAN|Japanese Accepted Name}}; developmental code name UCB-0942) is a synaptic vesicle glycoprotein 2A (SV2A) ligand which is under development for the treatment of epilepsy.{{cite web | title=Padsevonil | website=AdisInsight | date=5 November 2023 | url=https://adisinsight.springer.com/drugs/800033834 | access-date=26 February 2025}}{{cite web | title=Delving into the Latest Updates on Padsevonil with Synapse | website=Synapse | date=8 February 2025 | url=https://synapse.patsnap.com/drug/772ce12fe10843dc801998db442787b4 | access-date=26 February 2025}}{{cite journal | vauthors = Wu PP, Cao BR, Tian FY, Gao ZB | title = Development of SV2A Ligands for Epilepsy Treatment: A Review of Levetiracetam, Brivaracetam, and Padsevonil | journal = Neuroscience Bulletin | volume = 40 | issue = 5 | pages = 594–608 | date = May 2024 | pmid = 37897555 | doi = 10.1007/s12264-023-01138-2 | pmc = 11127901 }} It is much more potent than earlier SV2A ligands like levetiracetam and brivaracetam. However, in contrast to its predecessors, padsevonil's chemical structure has been modified such that it is no longer a racetam. In addition, padsevonil also interacts with synaptic vesicle glycoprotein 2B (SV2B) and 2C (SV2C). The drug is being developed by UCB. As of November 2023, it is in phase 2 clinical trials.